Beschreibung
Our study is the first to utilize the OpenVigil 2.1, a universal novel web-based pharmacovigilance analysis tool to analyze real-life safety and effectiveness of six ADHD medications with special emphasis on psychiatric adverse events. We accounted for the following ADHD medications; atomoxetine, lisdexamphetamine, amphetamine, methylphenidate (instant release, intermediate acting, long acting). We believe that thorough knowledge of adverse events for each medication helps to support treatment guidelines and clinical management of the events.
Autorenporträt
Doctorate of Clinical Pharmacy (Pharm.D.) The Hebrew University, Institute of Drug Research, Clinical Pharmacy Department, Jerusalem. Clinical Pharmacist and Pharmacotherapy lecturer specializing in internal medicine and clinical psychopharmacology.
Herstellerkennzeichnung:
OmniScriptum SRL
Str. Armeneasca 28/1, office 1
2012 Chisinau
MD
E-Mail: info@omniscriptum.com
